信邦制药(002390) - 2024 Q4 - 年度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for 2024 is projected to be between 86.17 million and 120.64 million CNY, representing a decrease of 58% to 70% compared to the previous year's profit of 287.23 million CNY[3] - The net profit after deducting non-recurring gains and losses is expected to be between 139.31 million and 187.53 million CNY, a decline of 30% to 48% from last year's 267.90 million CNY[3] - The basic earnings per share is forecasted to be between 0.04 CNY and 0.06 CNY, down from 0.15 CNY in the previous year[3] Revenue Decline - The decline in revenue is attributed to decreased income from the pharmaceutical distribution and medical services sectors, along with a drop in overall gross profit margin[5] Cost Management and Strategy - The company is implementing comprehensive budget management and enhancing cost control measures to improve operational cash flow and reduce period expenses[5] - Future strategies include focusing on the core medical and pharmaceutical business, improving medical technology and service quality, and strengthening the market competitiveness of traditional Chinese medicine products[5] Caution for Investors - The financial data in this earnings forecast has not been audited by registered accountants, and investors are advised to exercise caution[6]